Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)

A Phase II selection design trial was conducted to identify the most promising regimen for comparison with standard therapy in chemo-naive patients with unresectable or recurrent biliary tract cancer (JCOG0805). Gemcitabine plus S-1 therapy showed better efficacy than S-1 monotherapy with acceptable...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Jpn J Clin Oncol
Hlavní autoři: Mizusawa, Junki, Morizane, Chigusa, Okusaka, Takuji, Katayama, Hiroshi, Ishii, Hiroshi, Fukuda, Haruhiko, Furuse, Junji
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2016
Témata:
Clinical Trial Note
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4886137/
https://ncbi.nlm.nih.gov/pubmed/27025903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyv213
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky